Trial intelligence / Profile preview

CellCept Optimization to Reduce Coronary Heart Disease Risk in Renal Transplant Recipients

NCT01213394Phase 3Terminated

Start
Oct 2010
Primary completion
Oct 2011
Modality
Small Molecules
Countries
1
01

Overview

A Phase 3 trial of mycophenolate mofetil in kidney transplant rejection. Started Oct 2010; status: terminated.

02

Drugs

mycophenolate mofetil
03

Conditions

kidney transplant rejection

Beyond the preview

Go deeper on NCT01213394.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01213394.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call